Figure 4From: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejectionIHC staining for CD56 and CD8 in BCC from (a) P40 (imiquimod treated) and (b) P8 (vehicle-control). Lesions were graded blindly by two pathologists (AA and AF) and graded before and at EOT for peri-tumoral and intra-tumoral immune cells infiltrate. Cancer cells were evaluated separately for each marker. When BCC was absent at EOT as in P40 the immune infiltrate was compared to the peri-tumoral pre-treatment infiltrate. NE, not evaluable because no tumor cells were left at EOT.Back to article page